Primary chemotherapy in strongly suspected yolk sac tumor of the ovary

Abstract

We report a case of a right ovarian tumor measuring 10.8 ϫ 10 ϫ 8.5 cm (diagnosed as a yolk sac tumor) in a 31-year-old nulligravid woman with serum α-fetoprotein (AFP) level of 25 000 ng/ml and pleural effusion. Seven courses of primary chemotherapy (PVB; cisplatin, vinblastine, bleomycin) were given from May 16 to November 11, 1994. No surgical procedures were conducted. After the second course of PVB, the pleural effusion resolved; after the third course, the tumor disappeared, and after the fourth course, serum AFP decreased to the normal range. At the true of writing (May 11, 1998), the patient is in good health without recurrence, with an AFP level below 20 ng/ml. This paper reports, for the first time, a patient with yolk sac tumor in whom remission was achieved by primary chemotherapy alone.

Systematic Review of the Survival Outcomes of Neoadjuvant Chemotherapy in Women with Malignant Ovarian Germ Cell Tumors

“…The study selection was performed as shown in Figure 1 . A total of 141 articles were screened, and 15 studies, comprising 142 women with MOGCT treated with NACT versus 387 women with MOGCT treated without NACT, met the inclusion criteria for the present systematic review [ 5 , 6 , 7 , 9 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ]. After the identification of eligible studies, we checked the reference lists of all eligible studies and confirmed that potential citations/studies were not missed during the literature screening.…”

“…All of the included studies ( n = 15) were retrospective in nature and were published between 1999 and 2023. Of these 15 studies, 10 were original articles [ 9 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 36 , 37 ] and five were case reports [ 5 , 6 , 7 , 35 , 38 ]. Approximately half of the studies ( n = 8) were conducted in India [ 6 , 28 , 30 , 31 , 32 , 34 , 35 , 36 ], followed by China ( n = 2) [ 9 , 33 ] and others ( n = 1: England, France, Spain, Thailand, and Japan) [ 5 , 7 , 29 , 37 , 38 ].…”

“…Of these 15 studies, 10 were original articles [ 9 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 36 , 37 ] and five were case reports [ 5 , 6 , 7 , 35 , 38 ]. Approximately half of the studies ( n = 8) were conducted in India [ 6 , 28 , 30 , 31 , 32 , 34 , 35 , 36 ], followed by China ( n = 2) [ 9 , 33 ] and others ( n = 1: England, France, Spain, Thailand, and Japan) [ 5 , 7 , 29 , 37 , 38 ]. Four comparator studies compared NACT versus non-NACT use in women with MOGCT [ 9 , 30 , 32 , 34 ], and the remaining 11 were non-comparator studies.…”